Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong innovative drug sector, with the CSI Hong Kong Innovative Drug Index rising by 5.04% and individual stocks like Junsheng Tai Pharmaceutical-B and Innovent Biologics seeing significant gains [1] - The Hong Kong Innovative Drug ETF (513120) has shown a notable increase of 4.56%, marking its fourth consecutive rise, and has a trading volume of 2.369 billion yuan, indicating active market participation [1] - The latest market capitalization of the Hong Kong Innovative Drug ETF reached 9.855 billion yuan, making it the largest among Hong Kong pharmaceutical ETFs [1] Group 2 - In 2024, the total amount of License out authorization for Chinese innovative drugs surpassed 50 billion USD, reaching 51.9 billion USD, which represents a year-on-year growth of 27.4% and accounts for 30% of the global total in similar transactions [2] - The Chinese innovative drug sector has demonstrated strong investment value and growth potential, driven by policy support, technological advancements, and market recognition of high-quality pharmaceutical companies [2] - The shift in the industry focus from "quantity and speed" to "quality and innovation" has enhanced the overall R&D capabilities and product differentiation, establishing clear competitive barriers [2]
连续4日上涨，港股创新药ETF(513120)盘中涨幅居全市场ETF第二！权重股信达生物涨超17%